Evidence map›Paper›PMID 35960391›Full record

ArticleSurgical case reports2022

Pegfilgrastim-induced vasculitis of the subclavian and basilar artery complicated by subarachnoid hemorrhage in a breast cancer patient: a case report and review of the literature.

Yukiko Seto, Nobuyoshi Kittaka, Azusa Taniguchi, Haruka Kanaoka, Satomi Nakajima, Yuri Oyama, Hiroki Kusama, Noriyuki Watanabe, Saki Matsui, Minako Nishio and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Surgical case reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Yukiko SetoDepartment of Breast and Endocrine Surgery, Osaka International Cancer Institute, 3-1-69 Otemae Chuo-ku, Osaka, 541-8567, Japan.
Nobuyoshi KittakaDepartment of Breast and Endocrine Surgery, Osaka International Cancer Institute, 3-1-69 Otemae Chuo-ku, Osaka, 541-8567, Japan. nobuyoshi.kittaka@oici.jp.ORCID http://orcid.org/0000-0002-0906-1155
Azusa TaniguchiDepartment of Breast and Endocrine Surgery, Osaka International Cancer Institute, 3-1-69 Otemae Chuo-ku, Osaka, 541-8567, Japan.
Haruka KanaokaDepartment of Breast and Endocrine Surgery, Osaka International Cancer Institute, 3-1-69 Otemae Chuo-ku, Osaka, 541-8567, Japan.
Satomi NakajimaDepartment of Breast and Endocrine Surgery, Osaka International Cancer Institute, 3-1-69 Otemae Chuo-ku, Osaka, 541-8567, Japan.
Yuri OyamaDepartment of Breast and Endocrine Surgery, Osaka International Cancer Institute, 3-1-69 Otemae Chuo-ku, Osaka, 541-8567, Japan.
Hiroki KusamaDepartment of Breast and Endocrine Surgery, Osaka International Cancer Institute, 3-1-69 Otemae Chuo-ku, Osaka, 541-8567, Japan.
Noriyuki WatanabeDepartment of Breast and Endocrine Surgery, Osaka International Cancer Institute, 3-1-69 Otemae Chuo-ku, Osaka, 541-8567, Japan.
Saki MatsuiDepartment of Breast and Endocrine Surgery, Osaka International Cancer Institute, 3-1-69 Otemae Chuo-ku, Osaka, 541-8567, Japan.
Minako NishioDepartment of Medical Oncology, Osaka International Cancer Institute, Osaka, Japan.
Fumie FujisawaDepartment of Medical Oncology, Osaka International Cancer Institute, Osaka, Japan.
Koji TakanoDepartment of Neurosurgery, Osaka International Cancer Institute, Osaka, Japan.
Hideyuki AritaDepartment of Neurosurgery, Osaka International Cancer Institute, Osaka, Japan.
Takahiro NakayamaDepartment of Breast and Endocrine Surgery, Osaka International Cancer Institute, 3-1-69 Otemae Chuo-ku, Osaka, 541-8567, Japan.
Osaka International Cancer Institute · JPOsaka International Cancer Institute · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPegfilgrastim (PEG) is a sustained-duration pegylated form of filgrastim, a granulocyte-colony stimulating factor agent that is widely used as prophylaxis against febrile neutropenia during chemotherapy. We report the case of a breast cancer patient who developed PEG-induced vasculitis complicated by subarachnoid hemorrhage (SAH) and review the relevant literature. CASE PRESENTATION: A 48-year-old woman had undergone surgery for breast cancer and was receiving docetaxel and cyclophosphamide as adjuvant chemotherapy (docetaxel 75 mg/m

conclusionAlthough an uncommon adverse effect, vasculitis affecting vessels of various sizes may be caused by PEG. To the best of our knowledge, this report is the first to describe a case of G-CSF-induced vasculitis complicated by SAH. In cases of persistent high fever and elevated inflammatory response after PEG administration and in the absence of infection, clinicians should consider the possibility of drug-induced vasculitis.

Indexed as

Breast cancerGranulocyte-colony stimulating factorPegfilgrastimSubarachnoid hemorrhageVasculitis

Identifiers

PMID35960391
PMCPMC9374851
OpenAlexW4291396170

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.